Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial
Post-hoc evaluation of LEAP 2 study (n=736) found similar clinical success rates for oral lefamulin vs oral moxifloxacin for patients with Pneumonia Outcomes Research Team risk classes II‒IV (89-91% vs 88-91%) and CURB-65 score 2‒3 (87‒90% vs. 82‒88%).
Source:
Journal of Emergency Medicine
SPS commentary:
In May 2020, the European CHMP recommended approval of lefamulin (Xenleta), a pleuromutilin antibacterial which inhibits bacterial protein synthesis, available as infusion and tablets, for treatment of community-acquired pneumonia in adults. Approval was based on data from LEAP and LEAP 2 studies reporting non-inferiority to moxifloxacin +/- adjunctive linezolid.